259 related articles for article (PubMed ID: 27907175)
1. p53 Specifically Binds Triplex DNA In Vitro and in Cells.
Brázdová M; Tichý V; Helma R; Bažantová P; Polášková A; Krejčí A; Petr M; Navrátilová L; Tichá O; Nejedlý K; Bennink ML; Subramaniam V; Bábková Z; Martínek T; Lexa M; Adámik M
PLoS One; 2016; 11(12):e0167439. PubMed ID: 27907175
[TBL] [Abstract][Full Text] [Related]
2. Interaction in vitro of type III intermediate filament proteins with triplex DNA.
Li G; Tolstonog GV; Traub P
DNA Cell Biol; 2002 Mar; 21(3):163-88. PubMed ID: 12015895
[TBL] [Abstract][Full Text] [Related]
3. p53 Binds Preferentially to Non-B DNA Structures Formed by the Pyrimidine-Rich Strands of GAA·TTC Trinucleotide Repeats Associated with Friedreich's Ataxia.
Helma R; Bažantová P; Petr M; Adámik M; Renčiuk D; Tichý V; Pastuchová A; Soldánová Z; Pečinka P; Bowater RP; Fojta M; Brázdová M
Molecules; 2019 May; 24(11):. PubMed ID: 31159174
[TBL] [Abstract][Full Text] [Related]
4. High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops.
Stros M; Muselíková-Polanská E; Pospísilová S; Strauss F
Biochemistry; 2004 Jun; 43(22):7215-25. PubMed ID: 15170359
[TBL] [Abstract][Full Text] [Related]
5. tumor suppressor p53 binds with high affinity to CTG.CAG trinucleotide repeats and induces topological alterations in mismatched duplexes.
Walter K; Warnecke G; Bowater R; Deppert W; Kim E
J Biol Chem; 2005 Dec; 280(52):42497-507. PubMed ID: 16230356
[TBL] [Abstract][Full Text] [Related]
6. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53.
Kim E; Rohaly G; Heinrichs S; Gimnopoulos D; Meissner H; Deppert W
Oncogene; 1999 Dec; 18(51):7310-8. PubMed ID: 10602486
[TBL] [Abstract][Full Text] [Related]
7. Selective recognition of pyrimidine motif triplexes by a protein encoded by the bacterial transposon Tn7.
Rao JE; Craig NL
J Mol Biol; 2001 Apr; 307(5):1161-70. PubMed ID: 11292332
[TBL] [Abstract][Full Text] [Related]
8. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
Shivakumar CV; Das GC
Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
[TBL] [Abstract][Full Text] [Related]
9. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein.
Maiyar AC; Phu PT; Huang AJ; Firestone GL
Mol Endocrinol; 1997 Mar; 11(3):312-29. PubMed ID: 9058378
[TBL] [Abstract][Full Text] [Related]
10. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
11. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
12. Influence of GC and AT specific DNA minor groove binding drugs on intermolecular triplex formation in the human c-Ki-ras promoter.
Vigneswaran N; Mayfield CA; Rodu B; James R; Kim HG; Miller DM
Biochemistry; 1996 Jan; 35(4):1106-14. PubMed ID: 8573565
[TBL] [Abstract][Full Text] [Related]
13. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.
Jordan JJ; Menendez D; Inga A; Noureddine M; Bell DA; Resnick MA
PLoS Genet; 2008 Jun; 4(6):e1000104. PubMed ID: 18714371
[TBL] [Abstract][Full Text] [Related]
14. Recognition of Local DNA Structures by p53 Protein.
Brázda V; Coufal J
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208646
[TBL] [Abstract][Full Text] [Related]
15. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
Hansen S; Lane DP; Midgley CA
J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
[TBL] [Abstract][Full Text] [Related]
16. Presence of divalent cation is not mandatory for the formation of intramolecular purine-motif triplex containing human c-jun protooncogene target.
Kaushik S; Kaushik M; Svinarchuk F; Malvy C; Fermandjian S; Kukreti S
Biochemistry; 2011 May; 50(19):4132-42. PubMed ID: 21381700
[TBL] [Abstract][Full Text] [Related]
17. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter.
Benoit V; Hellin AC; Huygen S; Gielen J; Bours V; Merville MP
Oncogene; 2000 Sep; 19(41):4787-94. PubMed ID: 11032029
[TBL] [Abstract][Full Text] [Related]
18. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
19. The regulatory domain stabilizes the p53 tetramer by intersubunit contacts with the DNA binding domain.
Retzlaff M; Rohrberg J; Küpper NJ; Lagleder S; Bepperling A; Manzenrieder F; Peschek J; Kessler H; Buchner J
J Mol Biol; 2013 Jan; 425(1):144-55. PubMed ID: 23103206
[TBL] [Abstract][Full Text] [Related]
20. A phosphorylation-dependent switch in the disordered p53 transactivation domain regulates DNA binding.
Sun X; Dyson HJ; Wright PE
Proc Natl Acad Sci U S A; 2021 Jan; 118(1):. PubMed ID: 33443163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
